Welcome to our dedicated page for Moderna news (Ticker: MRNA), a resource for investors and traders seeking the latest updates and insights on Moderna stock.
Moderna, Inc. (NASDAQ: MRNA) is a biotechnology company focused on mRNA medicines, with multiple approved vaccines and a broad clinical pipeline. The MRNA news page on Stock Titan aggregates company announcements, investor updates and regulatory developments so readers can follow how Moderna’s strategy and pipeline progress translate into real-world events.
Investors and observers can use this feed to track commercial updates on products such as Spikevax, mRESVIA and mNEXSPIKE, along with developments in late-stage respiratory programs like the seasonal influenza vaccine mRNA-1010, the flu/COVID combination vaccine mRNA-1083 and the Norovirus vaccine candidate mRNA-1403. News items often cover regulatory submissions and opinions from agencies including the U.S. Food and Drug Administration, the European Medicines Agency, Health Canada and others.
The page also surfaces pipeline and clinical trial news in oncology and rare diseases, including updates on mRNA-4157 (intismeran autogene), mRNA-4359, mRNA-3927 for propionic acidemia and mRNA-3705 for methylmalonic acidemia. Announcements related to partnerships, such as CEPI’s funding commitment for the H5 pandemic influenza vaccine candidate mRNA-1018, appear here as well.
In addition, the MRNA news feed includes financial results, guidance and capital structure updates, such as quarterly earnings releases, multi-year financial frameworks and information on facilities like the $1.5 billion credit agreement. Corporate items, including participation in healthcare conferences, Analyst Day presentations and shareholder meeting outcomes, are also reflected.
By reviewing this consolidated news stream, readers can see how Moderna’s respiratory vaccine franchise, oncology and rare disease programs, manufacturing expansion and financing decisions evolve over time, all based on the company’s own disclosures and related announcements.
Moderna (MRNA) announced the publication of interim safety and primary efficacy results from its Phase 3 trial of the COVID-19 Vaccine (mRNA-1273) in the New England Journal of Medicine. The two-dose regimen demonstrated a vaccine efficacy of 94.1% against COVID-19, with 196 confirmed cases during the study. The trial enrolled over 30,000 participants and showed favorable tolerability and safety. The company is planning additional studies, including for adolescents and pregnant women, while continuing to follow participants for long-term safety data.
Moderna (Nasdaq: MRNA) has entered into a supply agreement with the Republic of Korea to provide 40 million doses of the Moderna COVID-19 Vaccine, aiming for deliveries to commence in May 2021. Currently, the vaccine is not approved for use in South Korea, necessitating regulatory approvals prior to distribution. CEO Stéphane Bancel emphasized the agreement as a step towards a lasting collaboration with Korea. Moderna's mRNA technology aims to transform patient care across various diseases, while the vaccine has received emergency use authorization in the U.S. for individuals 18 and older.
Moderna (MRNA) is in discussions with the South Korean government to supply 40 million COVID-19 vaccine doses, with distribution planned to start in Q2 2021. The vaccine has received emergency use authorization but is not fully approved by the FDA. Moderna focuses on mRNA therapeutics and vaccines across various diseases, supported by alliances with major pharmaceutical companies. However, the company acknowledges risks related to regulatory approval, manufacturing, and vaccine efficacy, which may impact its financial outlook.
Moderna (Nasdaq: MRNA) announced CEO Stéphane Bancel's virtual participation in the Goldman Sachs 13th Annual Healthcare CEOs Unscripted Conference on January 5, 2021, at 8:00 a.m. ET. A live webcast will be accessible in the Investors section on the Moderna website, with a replay available for 90 days post-event. Moderna is pioneering mRNA science to create transformative medicines, addressing various diseases through a robust pipeline of therapeutics and vaccines, in collaboration with strategic partners like AstraZeneca and Merck.
Moderna, Inc. (Nasdaq: MRNA) announced that Health Canada has authorized its COVID-19 vaccine for individuals 18 and older under an Interim Order. This decision reflects a comprehensive review, including data from the Phase 3 COVE study with 30,000 participants. The Canadian government has increased its confirmed order for the vaccine by 20 million doses, totaling 40 million doses. The vaccine, which utilizes mRNA technology, is designed to protect against COVID-19. Moderna emphasizes ongoing collaboration with regulatory bodies to ensure vaccine efficacy and safety.
Moderna (Nasdaq: MRNA) announced that the CDC's ACIP has recommended the use of its COVID-19 vaccine for individuals aged 18 and older under an Emergency Use Authorization (EUA). This recommendation follows previous guidelines prioritizing healthcare workers for vaccination. The vaccine has been authorized for distribution following FDA approval on December 18, 2020. Moderna aims to provide 100-125 million doses globally by Q1 2021, with 85-100 million for the U.S. Under Operation Warp Speed, 20 million doses are expected by December's end.
Moderna, Inc. (Nasdaq: MRNA) has received Emergency Use Authorization (EUA) from the FDA for its COVID-19 vaccine, mRNA-1273, for individuals aged 18 and older. Delivery of approximately 20 million doses to the U.S. government will begin immediately, with 100-125 million doses expected globally in Q1 2021. The vaccine demonstrated a 94.1% efficacy rate in a pivotal Phase 3 trial involving 30,000 participants. Moderna plans to file a Biologics License Application in 2021 to seek full licensure.
Moderna (Nasdaq: MRNA) announced that the European Commission has increased its order for the COVID-19 vaccine mRNA-1273 by 80 million doses, totaling 160 million doses. The initial deliveries are set to begin early 2021, pending regulatory approval from the EMA. The CEO expressed gratitude for this confidence, while Moderna has confirmed supply agreements totaling over 470 million doses across multiple countries. The company is preparing for distribution in case it receives market authorization.
Moderna, Inc. (Nasdaq:MRNA) announced that the FDA’s advisory committee recommended Emergency Use Authorization (EUA) for its COVID-19 vaccine candidate, mRNA-1273. The recommendation received an overwhelming positive vote with 20 in favor and 0 against. The vaccine demonstrated a 94.1% efficacy rate based on a Phase 3 clinical study involving over 30,000 participants. The company is aiding distribution efforts while ensuring that mRNA-1273 can be transported at standard refrigerator temperatures. The FDA will consider this recommendation for its final decision on EUA.
Moderna, Inc. (Nasdaq: MRNA) has reached an agreement with Singapore's Ministry of Health to supply mRNA-1273, its COVID-19 vaccine candidate. The Phase 3 COVE study, which included 30,000 participants, demonstrated an efficacy of 94.1% against COVID-19 and 100% against severe cases. Safety data reveal common reactions like fatigue and headache, primarily after the second dose. Moderna plans to deliver approximately 500 million doses annually, with potential scalability to up to 1 billion doses. The vaccine remains stable at refrigerator temperatures for 30 days.
FAQ
What is the current stock price of Moderna (MRNA)?
What is the market cap of Moderna (MRNA)?
